28.02.2007 15:02:00
|
Boston Scientific Announces Launch of Race Against Pain(SM) Campaign to Shine Spotlight on Pain Management Technology
NATICK, Mass., Feb. 28 /PRNewswire-FirstCall/ -- Boston Scientific Corporation announced today the launch of its Neuromodulation Group's Race Against Pain public outreach campaign to 50 million chronic pain sufferers in the United States. Inspired by Mike Roman - Formula race car driver, chronic pain patient and campaign spokesperson - the Race Against Pain campaign's mission is to educate sufferers about the importance of Pain Specialists and provide them with peer-to-peer support through http://www.raceagainstpain.com/. Boston Scientific will raise awareness through various mediums including media, Internet, industry conference speaking engagements, race events in 11 markets, health care professional events and patient outreach.
"Chronic pain costs society more than $100 billion annually and is the leading cause of adult disability in the U.S.," said Michael Onuscheck, President of Boston Scientific's Pain Management Business. "While all physicians treat pain, few specialize in pain management. The Race Against Pain campaign will help raise awareness for the under-recognized medical discipline of pain management and help guide chronic pain sufferers to possible solutions."
Roman, exhausted all pain treatment options, including powerful pain medications, drug pumps and single-source spinal cord stimulation (SCS) therapy. In 2005, he was successfully treated by a Pain Specialist with a new generation of SCS therapy, Boston Scientific's Precision(TM) multi-source spinal cord stimulation system. He has since eliminated pain medications from his daily regimen. Now dedicated to helping others who suffer from chronic pain, Roman works to shorten the amount of time it takes chronic pain sufferers to find a pain management solution.
"I endured more than 30 surgeries and four progressive amputations of my right leg in an attempt to manage my phantom limb pain," said Roman. "I lived in horrifying chronic pain for a decade before I finally found a medical professional who specialized in pain management. He provided me with options that other physicians didn't know about, and now I control my pain instead of it controlling me."
Boston Scientific is sponsoring Roman's race team and launching http://www.raceagainstpain.com/ to bring the message of hope to the 50 million other Americans who suffer from the effects of chronic pain. For information on the campaign, visit http://www.raceagainstpain.com/. For information on Precision Spinal Cord Stimulation therapy used by Mike Roman, visit http://www.controlyourpain.com/.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.
This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.
CONTACT: Paul Donovan 508-650-8541 (office) 508-667-5165 (mobile) Media Relations Boston Scientific Corporation Dan Brennan 508-650-8538 (office) 617-459-2703 (mobile) Investor Relations Boston Scientific Corporation
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Boston Scientific Corp.mehr Nachrichten
21.01.25 |
S&P 500-Wert Boston Scientific-Aktie: So viel hätten Anleger an einem Boston Scientific-Investment von vor 10 Jahren verdient (finanzen.at) | |
21.01.25 |
Erste Schätzungen: Boston Scientific öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) | |
14.01.25 |
S&P 500-Wert Boston Scientific-Aktie: So viel Gewinn hätte ein Boston Scientific-Investment von vor 5 Jahren eingefahren (finanzen.at) | |
08.01.25 |
S&P 500-Handel aktuell: S&P 500 bewegt sich zum Handelsende im Plus (finanzen.at) | |
08.01.25 |
Verluste in New York: Das macht der S&P 500 aktuell (finanzen.at) | |
08.01.25 |
Aufschläge in New York: Anleger lassen S&P 500 am Mittwochmittag steigen (finanzen.at) | |
08.01.25 |
Zurückhaltung in New York: S&P 500 präsentiert sich zum Start schwächer (finanzen.at) | |
07.01.25 |
S&P 500-Wert Boston Scientific-Aktie: So viel Gewinn hätte ein Investment in Boston Scientific von vor 3 Jahren eingefahren (finanzen.at) |
Analysen zu Boston Scientific Corp.mehr Analysen
Aktien in diesem Artikel
Boston Scientific Corp. | 96,50 | 0,00% |
Indizes in diesem Artikel
S&P 500 | 6 101,24 | -0,29% |